C&O Launches the First Rabeprazole Sodium for Injection (澳博平®) in China.

Shenzhen, 29 September 2014 – C & O Pharmaceutical Technology (Holdings) Limited ("C&O") today announces that it launches the first Rabeprazole Sodium for Injection (澳博平®) in China, which is developed by C&O itself.

Peptic ulcer is a global disease with high morbidity of around 10%. Among the patients suffers peptic ulcer bleeding, the proportion of high‐risk bleeding is high, accounting for 43.4%, and the risk of re‐bleeding is high too. The launch of Rabeprazole Sodium for Injection (澳博平®) provides a new choice of treatment of peptic ulcer for patients and medical institutions, and meets the growing market demand.

Proton‐pump inhibitors (PPIs) inhibit gastric acid secretion by blocking the final stage of gastric acid secretion. 澳博平® , developed by C&O, belongs to the second generation of proton pump inhibitors, is a new drug first launched in China. This new formulation offers a new option for the treatment of patients who suffer gastric ulcer or duodenal ulcer bleeding, who are not suitable for oral therapy.

Compared with other injectable proton pump inhibitors, 澳博平® has a rapid and long lasting acid suppression effect; Rabeprazole is less susceptible to metabolism of CYP450 drug metabolizing enzymes, and 澳 博平® has relative small differences in efficacy and minimal drug interaction.

Page Updated as at 29/9/14